The Cocktail Report (sounds really smart around your friends):
The federal Advanced Research Projects Agency for Health (ARPA-H) has awarded $38 million to UT Health San Antonio to lead a landmark five-year clinical trial called VITAL-H, testing three FDA-approved drugs for their ability to extend healthspan (the number of years a person lives in good health, free of serious disease and disability).
The three drugs being tested are rapamycin (originally an immunosuppressant that, at low doses, reduces inflammation and aging biomarkers), dapagliflozin (a diabetes drug that improves metabolic health and lowers cardiovascular risk), and semaglutide (the GLP-1 drug best known as Ozempic, which also reduces cardiovascular events).
The trial will enroll 726 adults in their 60s, comparing each drug against a placebo across four study arms. Enrollment begins next year.
- One of the trial's most significant ambitions is to get the FDA to officially recognize intrinsic capacity (a composite measure of physical and mental function) as a valid regulatory endpoint for aging research — a move that could accelerate approvals of future longevity therapies.
- Participants will take one pill daily, wear a health-tracking ring monitoring activity, heart health, and sleep, and complete in-person assessments at multiple sites across San Antonio.
Here is a development that puts longevity science on a new level: the U.S. federal government has committed $38 million to test whether drugs already sitting in pharmacies can measurably extend the healthy years of human life. The trial, called VITAL-H (Validation and Intervention Testing for Aging, Longevity and Healthspan), will be led by the Barshop Institute at UT Health San Antonio and is funded by ARPA-H, a federal agency designed to pursue high-impact health breakthroughs.
This is directly relevant to you because the drugs being tested are not experimental compounds years away from approval. They are medications already cleared by the FDA, being repurposed based on emerging evidence that they target the biological mechanisms of aging itself.
The trial will test three drugs in adults in their 60s: rapamycin, which at low doses shows consistent effects on inflammation and aging biomarkers; dapagliflozin, a diabetes drug with cardiovascular and metabolic benefits; and semaglutide, the GLP-1 receptor agonist (a class of drug that mimics a gut hormone to regulate blood sugar and appetite) known commercially as Ozempic. Each will be compared against a placebo to isolate its impact on healthy aging.
The underlying theory comes from geroscience, the field that studies aging as a single modifiable biological process rather than a collection of separate diseases. The concept is that targeting a small number of core aging mechanisms with one drug could influence many health outcomes at once.
One of the trial's most ambitious goals goes beyond the drugs themselves: researchers want the FDA to formally recognize intrinsic capacity (a composite measure of physical and mental function across five domains) as a valid regulatory endpoint. That designation would make it far easier to approve future longevity therapies, potentially changing the regulatory landscape for the entire field.
Participants will take one pill daily, wear a smart ring tracking activity, heart rate, and sleep, and complete assessments at sites across San Antonio. Enrollment is expected to begin in 2027.
Why Should You Care?
Most longevity research to date has lived in animal labs. This trial marks a major shift: a rigorous, federally funded, multi-site human study designed to answer the question that everyone in the field has been circling for years.
If even one of these three drugs demonstrates a measurable extension of healthspan in humans, it could reshape medical practice for an entire generation of adults currently in their 40s, 50s, and 60s. The results of VITAL-H may be among the most consequential health findings of this decade.
Sources:
UT Health San Antonio News: UT San Antonio to lead $38 million national trial testing drugs to extend healthspan, March 4, 2026
ARPA-H Proactive Solutions for Prolonging Resilience (PROSPR) program, U.S. Department of Health and Human Services
